Tags

Type your tag names separated by a space and hit enter

A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.

Abstract

Tizanidine was evaluated in a prospective, double-blind, randomized, placebo-controlled trial in 187 patients with MS. Taken orally for 9 weeks and preceded by a titration phase for a period of 3 weeks starting at 2 mg daily, tizanidine produced a significant reduction in spastic muscle tone compared with placebo treatment. Within the effective dose range of 24 to 36 mg given daily in three doses, tizanidine achieved a 20% mean reduction in muscle tone. Approximately 75% of patients, with all degrees of spasticity, reported subjective improvement without an increase in muscle weakness, but there was no improvement in activities of daily living depending on movement. Tizanidine achieved its maximum effect on spasticity within 1 week of the start of treatment; the benefit was maintained for at least 1 week after discontinuation of therapy. A variety of adverse events was recorded by patients taking tizanidine, but these were minor and reversible, and rarely limited treatment. Tizanidine is a well-tolerated and effective drug for symptomatic treatment of spasticity.

Links

  • Aggregator Full Text
  • Source

    Neurology 44:11 Suppl 9 1994 Nov pg S70-8

    MeSH

    Activities of Daily Living
    Adolescent
    Adult
    Aged
    Clonidine
    Double-Blind Method
    Female
    Humans
    Male
    Middle Aged
    Multiple Sclerosis
    Muscle Relaxants, Central
    Muscle Spasticity
    Muscle Tonus
    Pain
    Prospective Studies
    Reflex, Stretch
    Spasm

    Pub Type(s)

    Clinical Trial
    Journal Article
    Multicenter Study
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    7970014

    Citation

    "A Double-blind, Placebo-controlled Trial of Tizanidine in the Treatment of Spasticity Caused By Multiple Sclerosis. United Kingdom Tizanidine Trial Group." Neurology, vol. 44, no. 11 Suppl 9, 1994, pp. S70-8.
    A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology. 1994;44(11 Suppl 9):S70-8.
    (1994). A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology, 44(11 Suppl 9), pp. S70-8.
    A Double-blind, Placebo-controlled Trial of Tizanidine in the Treatment of Spasticity Caused By Multiple Sclerosis. United Kingdom Tizanidine Trial Group. Neurology. 1994;44(11 Suppl 9):S70-8. PubMed PMID: 7970014.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. PY - 1994/11/1/pubmed PY - 1994/11/1/medline PY - 1994/11/1/entrez SP - S70 EP - 8 JF - Neurology JO - Neurology VL - 44 IS - 11 Suppl 9 N2 - Tizanidine was evaluated in a prospective, double-blind, randomized, placebo-controlled trial in 187 patients with MS. Taken orally for 9 weeks and preceded by a titration phase for a period of 3 weeks starting at 2 mg daily, tizanidine produced a significant reduction in spastic muscle tone compared with placebo treatment. Within the effective dose range of 24 to 36 mg given daily in three doses, tizanidine achieved a 20% mean reduction in muscle tone. Approximately 75% of patients, with all degrees of spasticity, reported subjective improvement without an increase in muscle weakness, but there was no improvement in activities of daily living depending on movement. Tizanidine achieved its maximum effect on spasticity within 1 week of the start of treatment; the benefit was maintained for at least 1 week after discontinuation of therapy. A variety of adverse events was recorded by patients taking tizanidine, but these were minor and reversible, and rarely limited treatment. Tizanidine is a well-tolerated and effective drug for symptomatic treatment of spasticity. SN - 0028-3878 UR - https://www.unboundmedicine.com/medline/citation/7970014/A_double_blind_placebo_controlled_trial_of_tizanidine_in_the_treatment_of_spasticity_caused_by_multiple_sclerosis__United_Kingdom_Tizanidine_Trial_Group_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=7970014.ui DB - PRIME DP - Unbound Medicine ER -